International Journal of Hematology

, Volume 79, Issue 3, pp 221–228 | Cite as

Diagnosis and clinical management of chronic graft-versus-host disease

  • Paul J. Martin
  • Paul A. Carpenter
  • Jean E. Sanders
  • Mary E. D. Flowers
Progress in hematology


Chronic graft-versus-host disease (GVHD) occurs in approximately 60% of patients who survive for more than 100 days after receiving an allogeneic marrow or peripheral blood stem cell transplant without T-cell depletion of the graft. Chronic GVHD represents a major cause of morbidity and mortality among hematopoietic stem cell transplant recipients. Risk factors for the development of chronic GVHD and for mortality among patients who develop this complication have been defined, but the pathogenesis of chronic GVHD is not well understood.This review discusses the clinical manifestations that lead to a diagnosis of chronic GVHD and outlines an approach for therapy with glucocorticoids and extended administration of a calcineurin inhibitor. The judicious use of glucocorticoids at the lowest effective dose and alternate-day administration can minimize steroid-related side effects. Antibiotic prophylaxis to prevent infection and supportive care to minimize morbidity and prevent disability are critically important components in the management of patients with chronic GVHD. Approximately 50% of patients with chronic GVHD are able to discontinue immunosuppressive treatment within 5 years after the diagnosis, and 10% require continued treatment beyond 5 years. The remaining 40% die or develop recurrent malignancy before the chronic GVHD resolves. An improved understanding of the pathogenesis of the disease is needed to develop more effective therapy.

Key words

Hematopoietic cell transplantation Late effects Chronic graft-versus-host disease Immunosuppression 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sullivan KM. Graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. 2nd ed. Malden, Mass: Blackwell Science; 1999:515–536.Google Scholar
  2. 2.
    Socié G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. N Engl J Med. 1999;341:14–21.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versushost syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217.CrossRefGoogle Scholar
  4. 4.
    Antin J. Clinical practice: long-term care after hematopoietic-cell transplantation in adults. N Engl J Med. 2002;347:36–42.CrossRefGoogle Scholar
  5. 5.
    Vogelsang GB. How I treat chronic graft-versus-host disease. Blood. 2001;97:1196–1201.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–233.CrossRefGoogle Scholar
  7. 7.
    Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756–762.CrossRefGoogle Scholar
  8. 8.
    Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72:546–554.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Wingard JR, Piantadosi S, Vogelsang GB. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989;74:1428–1435.PubMedGoogle Scholar
  10. 10.
    Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood. 2001;97:1219–1226.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267–276.PubMedGoogle Scholar
  12. 12.
    Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348:727–734.CrossRefPubMedGoogle Scholar
  13. 13.
    Axelrod L. Glucocorticoid therapy. Medicine (Baltimore). 1976;55:39–65.CrossRefGoogle Scholar
  14. 14.
    Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. Blood. 1988;72:555–561.PubMedGoogle Scholar
  15. 15.
    Koc S, Leisenring W, Flowers MED, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100:48–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Flowers MED, Lee S, Vogelsang G. An update on how to treat chronic GVHD. Blood. 2003;102:2312.CrossRefPubMedGoogle Scholar
  17. 17.
    Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407–414.CrossRefPubMedGoogle Scholar
  18. 18.
    Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358–4366.CrossRefPubMedGoogle Scholar
  19. 19.
    Rosenthal P, Cotter J. The Boston Scleral Lens in the management of severe ocular surface disease. Ophthalmol Clin North Am. 2003;16:89–93.CrossRefPubMedGoogle Scholar
  20. 20.
    Flowers MED. Traditional treatment of chronic graft-versus-host disease. Blood Marrow Transplant Rev. 2002;12:5–8.Google Scholar
  21. 21.
    Flowers MED, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: longterm follow-up of a randomized trial. Blood. 2002;100:415–419.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Paul J. Martin
    • 1
    • 2
  • Paul A. Carpenter
    • 1
    • 2
  • Jean E. Sanders
    • 1
    • 2
  • Mary E. D. Flowers
    • 1
    • 2
  1. 1.Fred Hutchinson Cancer Research Center D2-100SeattleUSA
  2. 2.Departments of Medicine and PediatricsUniversity of WashingtonSeattleUSA

Personalised recommendations